Zai Lab (ZLAB) Q2 2024 earnings summary

Executive summary

• Net product revenue for Q2 2024 was $100.1 million, up 45% year-over-year, driven by VYVGART, ZEJULA, and NUZYRA sales, with VYVGART's strong launch and three new product approvals in China.

• 1H 2024 product revenue reached $187.3 million, up 42% year-over-year, with five commercial products marketed in Greater China.

• Net loss narrowed to $80.3 million in Q2 2024 from $120.9 million year-over-year, with loss per share improving to $0.08 from $0.13.

• Cash position at quarter-end was $730 million, supporting operations and business development through targeted profitability by end of 2025.

• Strategic partnerships, organizational changes, and pipeline expansion support commercial and R&D growth.

Financial highlights

• Q2 2024 net product revenue was $100.1 million, up from $68.9 million in Q2 2023 (45% increase, 47% constant currency); 1H 2024 revenue was $187.3 million, up 42% year-over-year.

• ZEJULA revenue was $45.0 million (+5% y-o-y), VYVGART $23.2 million (vs. $0.1 million y-o-y), NUZYRA $12.3 million (+165% y-o-y), QINLOCK $13.1 million (+49% for 1H 2024).

• R&D expenses decreased to $61.6 million in Q2 2024 (down 20% y-o-y); SG&A expenses increased to $79.7 million (up 17% y-o-y), mainly to support VYVGART.

• Net loss narrowed to $80.3 million in Q2 2024 (EPS loss $0.08), compared to $120.9 million (EPS loss $0.13) in Q2 2023; 1H 2024 net loss was $133.7 million (down 21% y-o-y).

• Cash and equivalents, short-term investments, and restricted cash totaled $730 million at quarter-end, down from $750.8 million at March 31, 2024.

Outlook and guidance

• Full-year VYVGART sales guidance raised to over $80 million, reflecting strong Q2 uptake and positive trends.

• Company expects to achieve profitability by end of 2025, driven by 50%+ compound annual revenue growth from 2023 to 2025.

• Multiple product launches and regulatory submissions expected in 2H 2024 and 2025, including KarXT for schizophrenia and bemarituzumab for gastric cancer.

• Subcutaneous VYVGART for CIDP anticipated to be approved by NMPA in next 12 months; NRDL listing for subQ formulation likely in 2026.

• Sufficient liquidity to fund operations for at least the next 12 months.